ライフサイエンスコーパス: acute heart failure

1 ardiovascular deaths and 89 readmissions for acute heart failure).

2 e and placebo in 2033 patients admitted with acute heart failure.

3 ed diagnostic and therapeutic strategies for acute heart failure.

4 ischemic ECG abnormalities in patients with acute heart failure.

5 cal trial data has shown benefit in treating acute heart failure.

6 e them to 180-day mortality in patients with acute heart failure.

7 y reduce 30-day recidivism for patients with acute heart failure.

8 siderosis but none relating to treatment of acute heart failure.

9 y measures, and designing clinical trials in acute heart failure.

10 ve clinical outcome signals in patients with acute heart failure.

11 ents who were stabilised after an episode of acute heart failure.

12 axin is showing potential as a treatment for acute heart failure.

13 ase III clinical trials for the treatment of acute heart failure.

14 lly the need to improve clinical outcomes in acute heart failure.

15 use in the broad population of patients with acute heart failure.

16 0.674 vs. 0.606, respectively, p < 0.001) in acute heart failure.

17 for early relief of dyspnea in patients with acute heart failure.

18 se outcomes, often develops in patients with acute heart failure.

19 e favorable clinical course in patients with acute heart failure.

20 e of hemodynamic monitoring in patients with acute heart failure.

21 ezosentan improves outcomes in patients with acute heart failure.

22 mptoms or clinical outcomes in patients with acute heart failure.

23 single-dose intravascular cocaine results in acute heart failure.

24 ical effects of tezosentan in the setting of acute heart failure.

25 ferences in risk for rehospitalization after acute heart failure.

26 e shown great potential for the treatment of acute heart failure.

27 Adjudicated diagnosis of acute heart failure.

28 ne patient with mucinous cardiopathy died of acute heart failure.

29 tunity to improve outcomes for patients with acute heart failure.

30 ve value of 75.0%, 65.7% to 82.5%) of having acute heart failure.

31 of action as forskolin and is used to treat acute heart failure.

32 le in determining prognosis in patients with acute heart failure.

33 rged from the ED with principal diagnosis of acute heart failure.

34 remains the cornerstone in the assessment of acute heart failure.

35 to diuretic treatment and worse prognosis in acute heart failure.

36 pe natriuretic peptide (BNPP) as a proxy for acute heart failure.

37 phocyte ratio, leading to inflamed milieu in acute heart failure.

38 tients seeking emergency department care for acute heart failure.

39 toms and in better outcomes in patients with acute heart failure.

40 f which is systemic iron overload leading to acute heart failure.

41 rmone that has been studied in patients with acute heart failure.

42 s of rolofylline to placebo in patients with acute heart failure.

43 nce of decongestive therapy in patients with acute heart failure.

44 as been associated with improved survival in acute heart failure.

45 n chronic heart failure and of new drugs for acute heart failure.

46 severe risk would improve the management of acute heart failure.

47 Serelaxin is a promising therapy for acute heart failure.

48 0.5%; p < 0.001), and showed higher rates of acute heart failure (45% vs. 38.3%; p = 0.005).

49 ; RR 0.98, 95% CI 0.66-1.45; low certainty), acute heart failure (5.38% vs 5.32%; RR 1.00, 95% CI 0.7

50 heart disease (5.5%; 95% CI: 4.5%-6.5%) and acute heart failure (5.4%; 95% CI: 4.4%-6.6%) were the m

51 of patients had an adjudicated diagnosis of acute heart failure (73.3% (2286/3119) and 29.0% (1802/6

52 -of-care algorithm to stratify patients with acute heart failure according to the risk of death.

53 Acute heart failure accounted for 2.2% (range: 0.3%-7.7%

54 igated a wide range of biomarker profiles in acute heart failure across the body mass index (BMI) spe

55 dity is highly prevalent among patients with acute heart failure across world regions, especially in

56 in, an emerging pharmaceutical treatment for acute heart failure, activates the relaxin family peptid

57 cted medication and close follow-up after an acute heart failure admission was readily accepted by pa

58 ohort of patients discharged from a previous acute heart failure admission.

59 ppb expression, which is required to prevent acute heart failure after infarction.

60 d additional tools to stratify patients with acute heart failure (AHF) according to risk.

61 g 4856 endocarditis patients, 1652 (34%) had acute heart failure (AHF) and 244 (5%) CS.

62 ing renal function (WRF) often occurs during acute heart failure (AHF) and can portend adverse outcom

63 g/dL, is a frequent finding in patients with acute heart failure (AHF) and has been associated with p

64 tic peptide (MR-proANP) for the diagnosis of acute heart failure (AHF) and the prognostic value of mi

65 resent to the emergency department (ED) with acute heart failure (AHF) are hospitalized.

66 lth literacy to recidivism for patients with acute heart failure (AHF) are not known.

67 Patients hospitalized for acute heart failure (AHF) continue to be discharged on a

68 Little is known about mode of death after acute heart failure (AHF) hospitalization.

69 differentiation of ischemic and nonischemic acute heart failure (AHF) in the emergency department (E

70 Acute heart failure (AHF) is a syndrome defined as the n

71 Acute heart failure (AHF) is associated with a poor prog

72 Patients hospitalized for acute heart failure (AHF) may receive different care dep

73 nischemic origin in patients presenting with acute heart failure (AHF) not resulting from acute myoca

74 renal function, and patient outcomes in the acute heart failure (AHF) population.

75 We report 5 cases of acute heart failure (AHF) related to multiple sclerosis

76 Acute heart failure (AHF) represents the most frequent c

77 30-day mortality in patients presenting with acute heart failure (AHF) to emergency departments (EDs)

78 d 1161 patients admitted to the hospital for acute heart failure (AHF) to evaluate the therapeutic ef

79 iratory flow rate (PEFR) would increase with acute heart failure (AHF) treatment over the first 24 h,

80 mics-related RNAs during hospitalization for acute heart failure (AHF) were rarely evaluated in vario

81 nsitional care intervention in patients with acute heart failure (AHF) who are discharged either dire

82 iated with adverse outcomes in patients with acute heart failure (AHF), attempts were made to deconge

83 In patients with acute heart failure (AHF), dyspnea relief is the most im

84 levated blood glucose level and mortality in acute heart failure (AHF).

85 n additional approach for decongestion after acute heart failure (AHF).

86 goal for optimal management of patients with acute heart failure (AHF).

87 have not improved outcomes in patients with acute heart failure (AHF).

88 gestion is associated with worse outcomes in acute heart failure (AHF).

89 proving the clinical course of patients with acute heart failure (AHF).

90 safety, and efficacy of OM in patients with acute heart failure (AHF).

91 ets, and hypochloremia predicts mortality in acute heart failure (AHF).

92 reason for hospitalization in patients with acute heart failure (AHF).

93 involving patients who were hospitalized for acute heart failure, an infusion of serelaxin did not re

94 rain natriuretic peptide in the diagnosis of acute heart failure and for improved clinical outcomes w

95 enrolled patients who were hospitalized for acute heart failure and had dyspnea, vascular congestion

96 ization should be reserved for patients with acute heart failure and impending respiratory or circula

97 gement continuum of patients presenting with acute heart failure and included heart failure cardiolog

98 When given to patients with acute heart failure and normal-to-increased blood pressu

99 For patients with acute heart failure and pleural effusion, a strategy of

100 on [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glo

101 Patients with acute heart failure and renal dysfunction demonstrate va

102 ries of renal function in 1962 patients with acute heart failure and renal dysfunction enrolled in th

103 In participants with acute heart failure and renal dysfunction, neither low-d

104 and preserve renal function in patients with acute heart failure and renal dysfunction; however, neit

105 is-guided diuretic protocol in patients with acute heart failure and signs of volume overload.

106 to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.

107 grated delivery system who visited an ED for acute heart failure and were discharged from January 1,

108 y, 4 patients had atrial fibrillation, 1 had acute heart failure, and 1 had incidental disease at aut

109 rs for chronic heart failure, nesiritide for acute heart failure, and cytochrome P-450 (CYP) 2C19 gen

110 Myocarditis, stress cardiomyopathy, acute heart failure, and direct injury from SARS-CoV-2 a

111 itis/myocarditis, ventricular dysfunction to acute heart failure, and even cardiogenic shock.

112 a multitude of causes, including arrhythmia, acute heart failure, and myocardial infarction.

113 , race, and sex as well as trends of sepsis, acute heart failure, and receipt of cardiac catheterizat

114 ught to examine the relationships among sex, acute heart failure, and related outcomes after STEMI in

115 primary driver of symptoms in patients with acute heart failure, and relief of congestion is a criti

116 iated with higher adjusted odds of peri-HSCT acute heart failure (aOR 2.64; 1.86-3.76; p < 0.0001), Q

117 gency department (ED) after an encounter for acute heart failure are at high risk for return hospital

118 Patients with acute heart failure are frequently or systematically hos

119 Interventions to improve management of acute heart failure are required at low-volume sites.

120 VB3 infection can cause cardiac arrhythmias, acute heart failure, as well as type 1 diabetes.

121 rospective validation study of patients with acute heart failure at 9 hospitals.

122 camtiv Mecarbil to Increase Contractility in Acute Heart Failure [ATOMIC-AHF]; NCT01300013).

123 (Biomarkers in Acute Heart Failure [BACH]; NCT00537628).

124 Among patients adjudicated to have acute heart failure, BNP, NT-proBNP, and MR-proANP conce

125 comorbidities) is common among patients with acute heart failure, but comprehensive global informatio

126 (serelaxin) has shown beneficial effects in acute heart failure, but its full therapeutic potential

127 ith baseline and worsening renal function in acute heart failure, but none has modeled the trajectori

128 ave been the mainstay of medical therapy for acute heart failure, but, in recent years, there has bee

129 during a hospital admission in patients with acute heart failure can improve their survival and reduc

130 generating capability and, in the setting of acute heart failure, can increase CO and mean arterial p

131 om any cardiac cause, myocardial infarction, acute heart failure, cardiac arrest, arrhythmia, complet

132 Frequently, the disease course is marked by acute heart failure, cardiogenic shock, intractable vent

133 Autopsy-defined SADs had no extracardiac or acute heart failure cause of death.

134 relations among end points typical in recent acute heart failure clinical trials were used.

135 age, 68+/-13 years; 22% black) enrolled in 3 acute heart failure clinical trials: ROSE-AHF (Renal Opt

136 Under acute heart failure conditions, both SMV and IABP assist

137 Acute heart failure confers a worse prognosis, and altho

138 Admissions for acute heart failure continue to increase but, to date, n

139 e heart failure patients, such as those with acute heart failure decompensation in the setting of cli

140 on is present in 50% to 80% of patients with acute heart failure, depending on image modality.

141 ied version of the risk-prediction model for acute heart failure developed from patients in the EFFEC

142 Patients enrolled in a large RCT of acute heart failure differed significantly based on clin

143 diuretic optimization strategy evaluation in acute heart failure (DOSE-AHF), enrolling patients hospi

144 (Renal Optimization Strategies Evaluation in Acute Heart Failure), DOSE-AHF (Diuretic Optimization St

145 group, dose-ranging study, 234 patients with acute heart failure, dyspnoea, congestion on chest radio

146 In patients with acute heart failure, early intervention with an intraven

147 of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890).

148 of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode [PIONEER-HF]; NCT02554890; C

149 on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode) trial demonstrated the effi

150 retic Peptide in Patients Stabilized From an Acute Heart Failure Episode) trial publication; (2) peri

151 on NT-pro BNP in Patients Stabilized From an Acute Heart Failure Episode), the in-hospital initiation

152 of NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode] trial) and >40% (PARAGLIDE-

153 Patients hospitalized for acute heart failure experience poor health status, inclu

154 nical variables to report the probability of acute heart failure for an individual patient was develo

155 (Renal Optimization Strategies Evaluation in Acute Heart Failure) found that when compared with place

156 nts were enrolled during hospitalisation for acute heart failure from 358 centres in 44 countries on

157 tted to hospital with a primary diagnosis of acute heart failure from 358 hospitals in 44 countries o

158 Patients with acute heart failure from 41 Spanish emergency department

159 Acute heart failure has an incidence ranging from 0.4% t

160 Acute heart failure has become a major medical issue in

161 Previous research in acute heart failure has primarily focused on the left ve

162 Many patients with acute heart failure have marked hypertension and preserv

163 Most patients admitted for acute heart failure have normal or increase blood pressu

164 Cardiorenal syndrome is common in acute heart failure (HF) and portends poor prognosis.

165 A total of 1077 patients hospitalized for acute heart failure (HF) and with a >10% NT-proBNP decre

166 GDF-15 (growth differentiation factor 15) in acute heart failure (HF) are limited.

167 Hospitalizations for acute heart failure (HF) are significant events with dow

168 Hospitalization for acute heart failure (HF) is associated with high rates o

169 We used data from 2 acute heart failure (HF) trials from the National Instit

170 It is unclear how patients hospitalized for acute heart failure (HF) who are long-term chronic HF su

171 transplantation, 10 unused donor hearts with acute heart failure (HF), 37 patients with chronic HF, a

172 receptor family member ST2 in patients with acute heart failure (HF).

173 tor antagonist, in patients hospitalized for acute heart failure (HF).

174 sponse is common in patients presenting with acute heart failure (HF).

175 of congestion and a predictor of outcomes in acute heart failure (HF).

176 osition and the splenic leukocyte profile in acute heart failure (HF).

177 redict rehospitalization after admission for acute heart failure (HF).

178 included those with a principal diagnosis of acute heart failure (ICD-9-CM 402 and 428; ICD-10 I50.x,

179 ed risk of 30-day mortality in patients with acute heart failure, identifying both high- and low-risk

180 ion (MI) in 2.9%, post MI in 20.6%, shock or acute heart failure in 3.0% and restenosis in 19.1%.

181 atory (embolic or aneurysm rupture) in 7 and acute heart failure in 4.

182 Acute heart failure in adults is the unfolding of heart

183 AMPD1 gene appears to be protective against acute heart failure in cardiac donors.

184 needed to identify effective treatments for acute heart failure in older patients.

185 rption and improved decongestive response in acute heart failure in the ADVOR trial.

186 ients 75 years and older with a diagnosis of acute heart failure in the ED from December 2018 to Sept

187 nical guidelines for the early management of acute heart failure in the emergency department (ED) set

188 Improved risk stratification of acute heart failure in the emergency department may info

189 One of the lung edema dogs expired of acute heart failure in the seventh hour of the experimen

190 lity in iron-deficient subjects admitted for acute heart failure), intravenous ferric carboxymaltose

191 icacy of a Standardized Diuretic Protocol in Acute Heart Failure) investigated the feasibility and ef

192 Acute heart failure is a common reason for admission, an

193 Acute heart failure is associated with a high post-disch

194 Hospitalization for acute heart failure is associated with high post-dischar

195 The first principle of management of acute heart failure is control of cardiac toxicity relat

196 ilure, but their effect on these outcomes in acute heart failure is not well characterized.

197 The cause of this acute heart failure is poorly understood.

198 The prognosis of acute heart failure is such that many children are consi

199 Acute heart failure is unusual in the pediatric populati

200 of cardiovascular death, cardiogenic shock, acute heart failure, life-threatening arrhythmias, resus

201 cross validation.ResultsIn participants with acute heart failure-like myocarditis (n = 31; mean age,

202 studies are warranted to better characterize acute heart failure management with UF in this populatio

203 r diuretic efficiency in black patients with acute heart failure may be related to racial differences

204 sses involving acute inflammation: COVID-19, acute heart failure, myocardial infarction, and stroke.

205 apabilities to diagnose and prognosticate in acute heart failure, natriuretic peptides are now being

206 in determining the pathogenesis of new-onset acute heart failure (new-AHF) when noninvasive testing i

207 s aged 18-85 years admitted to hospital with acute heart failure, not treated with full doses of guid

208 Acute heart failure occurred in 5 patients: 3 underwent

209 t cardiologists, the diagnostic accuracy for acute heart failure of BNP (B-type NP), NT-proBNP (N-ter

210 50 patients hospitalised with acute heart failure or acute coronary syndrome and with

211 cal complications, and rehospitalization for acute heart failure or acute myocardial infarction at 30

212 e myocardial infarction (AMI) complicated by acute heart failure or cardiogenic shock have high morta

213 ng heart failure, and readmission because of acute heart failure or death at 6 months.

214 or therapeutic dilemma or when encountering acute heart failure or hemodynamic lability refractory t

215 effective strategy for patients with AMI and acute heart failure or shock in whom medical therapy is

216 st, acute myocarditis that is complicated by acute heart failure or ventricular arrhythmias is associ

217 expertise and target various features of the acute heart failure patient, such as circulatory failure

218 In the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial, a 3-month

219 In the Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial, a novel 1

220 troponin T) identifies emergency department acute heart failure patients at low risk for rehospitali

221 arying site enrollment volume among all 7141 acute heart failure patients from the ASCEND-HF trial (A

222 Identifying low-risk acute heart failure patients safe for discharge from the

223 multicenter pilot study targeting lower risk acute heart failure patients to determine whether hsTnT

224 ntext of the Rehabilitation Therapy in Older Acute Heart Failure Patients trial physical rehabilitati

225 f mortality at both 7 and 30 days identified acute heart failure patients with a low risk of events.

226 ropes may be a necessary evil in a subset of acute heart failure patients, such as those with acute h

227 actice patterns, and in-hospital outcomes of acute heart failure patients.

228 The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase

229 a series of febrile pediatric patients with acute heart failure potentially associated with SARS-CoV

230 ables measured on admission in patients with acute heart failure predict a variety of adverse outcome

231 defects of the myocardium may predispose to acute heart failure presenting as AM, notably after comm

232 rimination in a broad group of patients with acute heart failure presenting to the ED.

233 f empagliflozin in patients hospitalized for acute heart failure produced clinical benefit regardless

234 of messaging to providers about treatment of acute heart failure (PROMPT-AHF) was a pragmatic, multic

235 study, which enrolled patients admitted with acute heart failure, regardless of ejection fraction or

236 The Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial enrolled 1161 pati

237 Acute heart failure resulting from cardiomyopathy has si

238 g adults with acute myocardial infarction or acute heart failure resulting in cardiogenic shock requi

239 Increasing Charlson score, LogEuroSCORE, acute heart failure, septic shock, and paravalvular comp

240 helin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies, 2 independent, identical, a

241 using global statistical methods in phase II acute heart failure studies.

242 The recently published BACH (Biomarkers in Acute Heart Failure) study demonstrated that MR-proADM h

243 y and Safety of Relaxin for the Treatment of Acute Heart Failure) study, serelaxin, the recombinant f

244 Myocarditis is an underdiagnosed cause of acute heart failure, sudden death, and chronic dilated c

245 Patients who present with acute heart failure suffer from a severe complication of

246 Although most research on patients with acute heart failure syndrome (AHFS) has focused on readm

247 nities of emergency department management of acute heart failure syndrome (AHFS).

248 cardiomyopathy is an increasingly recognized acute heart failure syndrome precipitated by intense emo

249 Takotsubo syndrome (TTS) is an acute heart failure syndrome with significant rates of i

250 This condition represents an acute heart failure syndrome with substantial morbidity

251 asurements, in patients hospitalized with an acute heart failure syndrome.

252 Acute heart failure syndromes (AHFS) have emerged as a l

253 d regional differences in clinical trials of acute heart failure syndromes (AHFS) have not been well

254 Acute heart failure syndromes (AHFS) remain a major caus

255 Acute heart failure syndromes (AHFS), with a high post-d

256 ns (cTn) may be elevated among patients with acute heart failure syndromes (AHFS).

257 Although acute heart failure syndromes are commonly defined as a

258 In patients with acute heart failure syndromes, a simple assessment of PV

259 gle most important goal in the management of acute heart failure syndromes.

260 nts have higher rates of hospitalization for acute heart failure than other race/ethnic groups.

261 In patients with acute heart failure, the addition of hydrochlorothiazide

262 ailure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical tr

263 an 78 years [Q1, Q3: 68,84]) presenting with acute heart failure to 86 hospital emergency departments

264 g the holy grail of evaluating patients with acute heart failure to being all but extinct.

265 ial, we randomly assigned 2157 patients with acute heart failure to receive a continuous intravenous

266 ned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or plac

267 ariables, measured at hospital admission for acute heart failure, to determine whether a few selected

268 laxin should be pursued in larger studies of acute heart failure, to identify an optimum dose, and to

269 gh intravenous diuretics is a cornerstone of acute heart failure treatment (AHF), its optimal initial

270 and who were stabilised after an episode of acute heart failure, treatment with ferric carboxymaltos

271 mber of participants enrolled per site in an acute heart failure trial is associated with participant

272 In this large, acute heart failure trial, site enrollment correlated wi

273 The BACH (Biomarkers in Acute Heart Failure) trial was a prospective, 15-center,

274 Most international acute heart failure trials have failed to show benefit w

275 llenges to be considered in design of future acute heart failure trials.

276 In patients with acute heart failure, ularitide exerted favorable physiol

277 ventricular ejection fraction</=35%) died of acute heart failure unrelated to ventricular arrhythmias

278 Among older patients with acute heart failure, use of a guideline-based comprehens

279 patients with chronic heart failure or mild acute heart failure, use of the reduction in pulmonary a

280 haracteristics, management, and prognosis of acute heart failure using a single protocol.

281 guideline recommended thresholds to diagnose acute heart failure varied substantially in important pa

282 d diuretic protocol to guide decongestion in acute heart failure was feasible, safe, and resulted in

283 Acute heart failure was induced in 6 of the pigs by snar

284 rehospitalization due to cardiac reasons and acute heart failure was similar in both groups at 1 year

285 models of diffuse myocardial damage causing acute heart failure, we show that eCSCs restore cardiac

286 evel data for 10 369 patients with suspected acute heart failure were pooled for the meta-analysis to

287 Patients hospitalized for acute heart failure were randomized to empagliflozin 10

288 ed trials in which patients hospitalized for acute heart failure were randomized within 16 h to intra

289 A cohort of patients with acute heart failure who presented to 4 emergency departm

290 In this secondary analysis, patients with acute heart failure who received a tailored, self-care i

291 enrolling patients admitted to hospital for acute heart failure who were randomly assigned (1:1) via

292 Among patients with acute heart failure who were seeking emergency care, the

293 ged 18 years or older, were hospitalised for acute heart failure with concomitant iron deficiency (de

294 ed trial involving patients hospitalized for acute heart failure with impaired renal function.

295 s followed up after a hospital discharge for acute heart failure with reduced ejection fraction (HFrE

296 It does not show promise in the treatment of acute heart failure with renal dysfunction.

297 Treatment of acute heart failure with serelaxin was associated with d

298 INTERPRETATION: Treatment of acute heart failure with serelaxin was associated with d

299 gly, these embryos die in mid-gestation from acute heart failure, with reduced proliferation of ventr

300 A third animal died of acute heart failure within 2 minutes of seizure onset, a